サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：胃食道逆流症治療薬の世界市場規模調査＆予測、薬剤タイプ別（制酸剤、H2受容体遮断剤、プロトンポンプ阻害剤（PPI）、プロキネティック剤）、地域別分析、2022-2029年
市場調査レポート
商品コード
1258052

胃食道逆流症治療薬の世界市場規模調査＆予測、薬剤タイプ別（制酸剤、H2受容体遮断剤、プロトンポンプ阻害剤（PPI）、プロキネティック剤）、地域別分析、2022-2029年

Global Gastroesophageal Reflux Disease Therapeutics Market Size study & Forecast, by Drug Type (Antacids, H2 Receptor Blockers, Proton Pump Inhibitors (PPIs), Pro-kinetic agents), and Regional Analysis, 2022-2029
出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.65円
胃食道逆流症治療薬の世界市場規模調査＆予測、薬剤タイプ別（制酸剤、H2受容体遮断剤、プロトンポンプ阻害剤（PPI）、プロキネティック剤）、地域別分析、2022-2029年
出版日: 2023年04月01日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

胃食道逆流症治療薬の世界市場は、2021年に51億8,000万米ドルと評価され、予測期間2022-2029年には1.76%以上の健全な成長率で成長すると予測されています。

胃食道逆流症（GERD）は、胃酸などの内容物が食道に逆流し、胸やけ、逆流、嚥下困難などの症状を引き起こす慢性疾患です。通常、下部食道括約筋（LES）と呼ばれる筋肉の輪が、胃の内容物が食道に逆流するのを防いでいますが、GERDではこの輪が弱まったり緩んだりして、胃酸や内容物が食道へ逃げてしまうのです。GERDは、肥満、妊娠、特定の薬、食道裂孔ヘルニア（胃の一部が横隔膜を通して胸に押し上げられる症状）など、さまざまな要因で引き起こされる可能性があります。GERDの治療には、通常、生活習慣の改善（原因となる食品を避ける、体重を減らす、禁煙するなど）と、胃酸の量を減らすための薬物療法が行われます。重症の場合は、LESを強化したり、食道裂孔ヘルニアを修復するための手術が必要になることもあります。GERD治療薬の目標は、胃酸の量を減らし、症状の重さを軽減することです。市場の需要は、主に、高齢者人口の増加、患者やヘルスケアプロバイダーのGERDとそれに関連する症状に対する認識の高まり、早期診断と治療につながっている、ひいてはGERD治療薬の需要を牽引している、といった要因によってもたらされます。

また、食生活の変化、肥満率の増加、高齢化などを主な原因として、世界的にGERDの有病率が増加しています。その結果、治療を希望する患者数が増加し、GERD治療薬の需要を牽引しています。米国国立医学図書館の報告によると、世界では2019年に7億8,395万人のGERD患者が発生しているため、ひいてはこれらの要因が世界市場におけるGERD治療薬の需要をエスカレートさせると予想されます。さらに、低侵襲手術や内視鏡治療など、GERD治療法の技術的進歩が著しく、これらの治療法の需要を牽引しているほか、入手が容易で手頃な価格のため、OTC GERD治療薬の需要が増加しています。このため、企業はGERD治療薬市場で一般用医薬品を拡大する機会を得ており、今後数年間は市場成長の好機となります。しかし、貧弱な医薬品パイプラインと患者の死亡率が、2022-2029年の予測期間における市場成長を制限しています。

胃食道逆流症治療薬の世界市場調査において考慮された主要地域は、アジア太平洋地域、北米、欧州、中南米、その他世界の地域です。北米は、人口増加に伴うGERD治療薬の使用増加により、売上高で市場を独占しています。一方、アジア太平洋地域は、予測期間中に最も高い成長率で成長すると予想されています。GERDの罹患率の上昇、対象市場における治療に関する知識の向上、主要な市場参入企業による製品ラインの多様化などの要因が、予測期間における市場成長を加速させています。

本調査の目的は、近年におけるさまざまなセグメントと国の市場規模を明らかにし、今後数年間の市場規模を予測することにあります。本レポートは、調査対象国の産業の質的・量的な側面を取り込むよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題など、重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場での潜在的な機会も組み込んでいます。.

目次

第1章 エグゼクティブサマリー

  • マーケットスナップショット
  • 世界・セグメント別市場推定・予測、2019年～2029年
    • 胃食道逆流症治療薬市場、地域別、2019-2029年
    • 胃食道逆流症治療薬市場、薬剤タイプ別、2019年～2029年
  • 主な動向
  • 調査手法
  • 調査の前提条件

第2章 胃食道逆流症治療薬の世界市場の定義と範囲

  • 調査目的
  • 市場の定義と範囲
    • 調査対象範囲
    • 産業の進化
  • 本調査の対象となった年
  • 通貨換算レート

第3章 胃食道逆流症治療薬の世界市場力学

  • 胃食道逆流症治療薬市場のインパクト分析（2019年～2029年）
    • 市場促進要因
      • 老年人口の増加
      • GERD治療薬に対する意識の高まり
      • GERDの有病率の増加
    • 市場の課題
      • 薬物療法のパイプラインが悪く、患者の死亡率が高いです
    • 市場のチャンス
      • GERD治療オプションの技術的進歩
      • 一般用医薬品（OTC）GERD治療薬の需要の増加

第4章 胃食道逆流症治療薬の世界市場産業分析

  • ポーターの5フォースモデル
    • 供給企業の交渉力
    • 買い手の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係
  • ポーターの5フォースモデルへの未来的アプローチ（2019-2029年）
  • PEST分析
    • 政治的
    • 経済的
    • ソーシャル
    • テクニカル
  • 主な投資機会
  • 主要成功戦略
  • 業界関係者見通し
  • アナリストの提言と結論

第5章 リスク評価：COVID-19の影響

  • COVID-19が業界に与える全体的な影響についての評価
  • COVID-19以前とCOVID-19以後の市場シナリオ

第6章 胃食道逆流症治療薬の世界市場：薬剤タイプ別

  • マーケットスナップショット
  • 胃食道逆流症治療薬の世界市場：薬剤タイプ別、業績-潜在能力分析
  • 胃食道逆流症治療薬の世界市場薬剤タイプ別推定・予測2019-2029
  • 胃食道逆流症治療薬市場、サブセグメント分析
    • 制酸剤
    • H2レセプターブロッカー
    • プロトンポンプ阻害剤（PPI）
    • プロキネティック剤

第7章 胃食道逆流症治療薬の世界市場：地域別分析

  • 胃食道逆流症治療薬市場、地域別市場スナップショット
  • 北米
    • 米国
      • 薬剤タイプ別の推定・予測、2019年～2029年
    • カナダ
  • 欧州胃食道逆流症治療薬市場スナップショット
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • アジア太平洋の胃食道逆流症治療薬市場スナップショット
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカ胃食道逆流症治療薬市場スナップショット
    • ブラジル
    • メキシコ
    • その他ラテンアメリカ地域
  • 世界のその他の地域

第8章 競合情報

  • 主な市場戦略
  • 企業プロファイル
    • GlaxoSmithKline plc
      • 主要な情報
      • 概要
      • 財務（データの入手が可能な場合のみ）
      • 製品概要
      • 最近の動向
    • Pfizer, Inc.
    • Sanofi S.A.
    • Johnson & Johnson Pvt. Ltd.
    • Glenmark Pharmaceuticals Ltd
    • Camber Pharmaceuticals, Inc.
    • Takeda Pharmaceutical Company Limited.
    • Ironwood Pharmaceuticals, Inc.
    • Phathom Pharmaceuticals, Inc.
    • Adcock Ingram

第9章 調査のプロセス

  • 調査プロセス
    • データマイニング
    • 分析
    • 市場推定
    • バリデーション
    • 出版
  • 調査の特徴
  • 調査の前提条件
図表

LIST OF TABLES

  • TABLE 1. Global Gastroesophageal Reflux Disease Therapeutics Market, report scope
  • TABLE 2. Global Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by Region 2019-2029 (USD Billion)
  • TABLE 3. Global Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by Drug Type 2019-2029 (USD Billion)
  • TABLE 4. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 5. Global Gastroesophageal Reflux Disease Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 6. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 7. Global Gastroesophageal Reflux Disease Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 8. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 9. Global Gastroesophageal Reflux Disease Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 10. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 11. Global Gastroesophageal Reflux Disease Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 12. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 13. Global Gastroesophageal Reflux Disease Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 14. U.S. Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 15. U.S. Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 16. U.S. Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 17. Canada Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 18. Canada Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 19. Canada Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 20. UK Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 21. UK Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 22. UK Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 23. Germany Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 24. Germany Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 25. Germany Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 26. France Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 27. France Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 28. France Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 29. Italy Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 30. Italy Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 31. Italy Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 32. Spain Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 33. Spain Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 34. Spain Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 35. RoE Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 36. RoE Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 37. RoE Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 38. China Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 39. China Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 40. China Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 41. India Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 42. India Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 43. India Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 44. Japan Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 45. Japan Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 46. Japan Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 47. South Korea Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 48. South Korea Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 49. South Korea Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 50. Australia Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 51. Australia Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 52. Australia Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 53. RoAPAC Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 54. RoAPAC Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 55. RoAPAC Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 56. Brazil Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 57. Brazil Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 58. Brazil Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 59. Mexico Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 60. Mexico Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 61. Mexico Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 62. RoLA Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 63. RoLA Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 64. RoLA Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 65. Row Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 66. Row Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 67. Row Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 68. List of secondary sources, used in the study of global Gastroesophageal Reflux Disease Therapeutics Market
  • TABLE 69. List of primary sources, used in the study of global Gastroesophageal Reflux Disease Therapeutics Market
  • TABLE 70. Years considered for the study
  • TABLE 71. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Gastroesophageal Reflux Disease Therapeutics Market, research methodology
  • FIG 2. Global Gastroesophageal Reflux Disease Therapeutics Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Gastroesophageal Reflux Disease Therapeutics Market, key trends 2021
  • FIG 5. Global Gastroesophageal Reflux Disease Therapeutics Market, growth prospects 2022-2029
  • FIG 6. Global Gastroesophageal Reflux Disease Therapeutics Market, porters 5 force model
  • FIG 7. Global Gastroesophageal Reflux Disease Therapeutics Market, pest analysis
  • FIG 8. Global Gastroesophageal Reflux Disease Therapeutics Market, value chain analysis
  • FIG 9. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 10. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 11. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 12. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 13. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 14. Global Gastroesophageal Reflux Disease Therapeutics Market, regional snapshot 2019 & 2029
  • FIG 15. North America Gastroesophageal Reflux Disease Therapeutics Market 2019 & 2029 (USD Billion)
  • FIG 16. Europe Gastroesophageal Reflux Disease Therapeutics Market 2019 & 2029 (USD Billion)
  • FIG 17. Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market 2019 & 2029 (USD Billion)
  • FIG 18. Latin America Gastroesophageal Reflux Disease Therapeutics Market 2019 & 2029 (USD Billion)
  • FIG 19. Global Gastroesophageal Reflux Disease Therapeutics Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

目次

Global Gastroesophageal Reflux Disease Therapeutics Market is valued at approximately USD 5.18 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 1.76% over the forecast period 2022-2029. Gastroesophageal reflux disease (GERD) is a chronic condition in which stomach acid and other contents flow back up into the esophagus, causing symptoms such as heartburn, regurgitation, and difficulty swallowing. Normally, a muscular ring called the lower esophageal sphincter (LES) prevents stomach contents from flowing back into the esophagus, but in GERD, this ring is weakened or relaxed, allowing stomach acid and other contents to escape into the esophagus. GERD can be caused by a variety of factors, including obesity, pregnancy, certain medications, and a hiatal hernia (a condition in which part of the stomach pushes up into the chest through the diaphragm). Treatment for GERD typically involves lifestyle modifications (such as avoiding trigger foods, losing weight, and quitting smoking) and medications to reduce the amount of acid in the stomach. In severe cases, surgery may be necessary to strengthen the LES or repair a hiatal hernia. The goal of GERD therapeutics is to reduce the amount of acid in the stomach and decrease the severity of symptoms. The market demand is primarily driven by the factors such as the increasing geriatric population, coupled with increasing awareness of GERD and its associated symptoms among patients and healthcare providers, which is leading to earlier diagnosis and treatment which in turn is driving the demand for GERD therapeutics.

In addition, the increasing prevalence of GERD is increasing worldwide, primarily due to changing dietary habits, increasing obesity rates, and an aging population. This has resulted in a growing patient population seeking treatment, which is driving the demand for GERD therapeutics. The National Library of Medicine reported that globally, there were 783.95 million GERD cases in 2019, thus, in turn, these factors are expected to escalate the demand for GERD Therapeutics in the global market. Furthermore, there have been significant technological advancements in GERD treatment options, such as minimally invasive surgery and endoscopic treatments, which are driving the demand for these treatments, as well as there is increasing demand for OTC GERD medications due to their easy availability and affordability. This presents an opportunity for companies to expand their OTC offerings in the GERD therapeutics market presenting lucrative opportunities for market growth over the forthcoming years. However, poor medication pipeline and patient mortality are restricting the market growth over the forecast period of 2022-2029.

The key regions considered for the Global Gastroesophageal Reflux Disease Therapeutics Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the growing use of GERD therapeutics as a result of the disease's rising incidence in the local population. Whereas, Asia Pacific is also expected to grow at the highest growth rate over the forecasting period. Factors such as rising incidences of the ailment, rising knowledge of its treatment among the target market, and rising emphasis on the part of major market participants to diversify their product lines are burgeoning the market growth in the forecasting years.

Major market players included in this report are:

  • GlaxoSmithKline plc
  • Pfizer, Inc.
  • Sanofi S.A.
  • Johnson & Johnson Pvt. Ltd.
  • Glenmark Pharmaceuticals Ltd
  • Camber Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited.
  • Ironwood Pharmaceuticals, Inc.
  • Phathom Pharmaceuticals, Inc.
  • Adcock Ingram

Recent Developments in the Market:

  • In July 2022, Adcock Ingram introduced dexlansoprazole modified release, a novel proton pump inhibitor. Professor Ronnie Fass of Ohio's Case Western Reserve University delivered the event's keynote address (United States). Prof. Fass is a recognised authority in gastroesophageal reflux disease and its diagnosis and treatment (GERD).
  • In June 2022, Glenmark Pharmaceuticals Ltd acquired the authorized generic versions of some over-the-counter medications from Wockhardt Ltd in the United States. The company's wholly-owned subsidiary Glenmark Pharmaceuticals Inc. in the USA has acquired the approved abbreviated new drug applications (ANDAs) for famotidine tablets (10 mg and 20 mg) used to treat and prevent ulcers in the stomach and intestine, as well as Lansoprazole delayed-release capsules USP, 15 mg, a medication used to treat indigestion, heartburn, and acid reflux.
  • In March 2022, Phantom Pharmaceuticals' FDA-approved medication Vonoprazan, which was created for the treatment of GERD, is now offered over the counter in Japan and other Asian nations. Also, due to the rising demand for GERD therapies in the region, a number of firms have increased their presence in Asia.

Global Gastroesophageal Reflux Disease Therapeutics Market Report Scope:

  • Historical Data: 2019-2020-2021
  • Base Year for Estimation: 2021
  • Forecast period: 2022-2029
  • Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: Drug Type, Region
  • Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World
  • Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Drug Type:

  • Antacids
  • H2 Receptor Blockers
  • Proton Pump Inhibitors (PPIs)
  • Pro-kinetic agents

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • ROLA
  • Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
    • 1.2.1. Gastroesophageal Reflux Disease Therapeutics Market, by Region, 2019-2029 (USD Billion)
    • 1.2.2. Gastroesophageal Reflux Disease Therapeutics Market, by Drug Type, 2019-2029 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Gastroesophageal Reflux Disease Therapeutics Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Gastroesophageal Reflux Disease Therapeutics Market Dynamics

  • 3.1. Gastroesophageal Reflux Disease Therapeutics Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing geriatric population.
      • 3.1.1.2. Rising awareness towards GERD Therapeutics.
      • 3.1.1.3. Increasing prevalence of GERD.
    • 3.1.2. Market Challenges
      • 3.1.2.1. Poor medication pipeline and patient mortality.
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Technological advancements in GERD treatment options.
      • 3.1.3.2. Increasing demand for over-the-counter (OTC) GERD medications

Chapter 4. Global Gastroesophageal Reflux Disease Therapeutics Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. Industry Experts Prospective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Gastroesophageal Reflux Disease Therapeutics Market, by Drug Type

  • 6.1. Market Snapshot
  • 6.2. Global Gastroesophageal Reflux Disease Therapeutics Market by Drug Type, Performance - Potential Analysis
  • 6.3. Global Gastroesophageal Reflux Disease Therapeutics Market Estimates & Forecasts by Drug Type 2019-2029 (USD Billion)
  • 6.4. Gastroesophageal Reflux Disease Therapeutics Market, Sub Segment Analysis
    • 6.4.1. Antacids
    • 6.4.2. H2 Receptor Blockers
    • 6.4.3. Proton Pump Inhibitors (PPIs)
    • 6.4.4. Pro-kinetic agents

Chapter 7. Global Gastroesophageal Reflux Disease Therapeutics Market, Regional Analysis

  • 7.1. Gastroesophageal Reflux Disease Therapeutics Market, Regional Market Snapshot
  • 7.2. North America Gastroesophageal Reflux Disease Therapeutics Market
    • 7.2.1. U.S. Gastroesophageal Reflux Disease Therapeutics Market
      • 7.2.1.1. Drug Type breakdown estimates & forecasts, 2019-2029
    • 7.2.2. Canada Gastroesophageal Reflux Disease Therapeutics Market
  • 7.3. Europe Gastroesophageal Reflux Disease Therapeutics Market Snapshot
    • 7.3.1. U.K. Gastroesophageal Reflux Disease Therapeutics Market
    • 7.3.2. Germany Gastroesophageal Reflux Disease Therapeutics Market
    • 7.3.3. France Gastroesophageal Reflux Disease Therapeutics Market
    • 7.3.4. Spain Gastroesophageal Reflux Disease Therapeutics Market
    • 7.3.5. Italy Gastroesophageal Reflux Disease Therapeutics Market
    • 7.3.6. Rest of Europe Gastroesophageal Reflux Disease Therapeutics Market
  • 7.4. Asia-Pacific Gastroesophageal Reflux Disease Therapeutics Market Snapshot
    • 7.4.1. China Gastroesophageal Reflux Disease Therapeutics Market
    • 7.4.2. India Gastroesophageal Reflux Disease Therapeutics Market
    • 7.4.3. Japan Gastroesophageal Reflux Disease Therapeutics Market
    • 7.4.4. Australia Gastroesophageal Reflux Disease Therapeutics Market
    • 7.4.5. South Korea Gastroesophageal Reflux Disease Therapeutics Market
    • 7.4.6. Rest of Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market
  • 7.5. Latin America Gastroesophageal Reflux Disease Therapeutics Market Snapshot
    • 7.5.1. Brazil Gastroesophageal Reflux Disease Therapeutics Market
    • 7.5.2. Mexico Gastroesophageal Reflux Disease Therapeutics Market
    • 7.5.3. Rest of Latin America Gastroesophageal Reflux Disease Therapeutics Market
  • 7.6. Rest of The World Gastroesophageal Reflux Disease Therapeutics Market

Chapter 8. Competitive Intelligence

  • 8.1. Top Market Strategies
  • 8.2. Company Profiles
    • 8.2.1. GlaxoSmithKline plc
      • 8.2.1.1. Key Information
      • 8.2.1.2. Overview
      • 8.2.1.3. Financial (Subject to Data Availability)
      • 8.2.1.4. Product Summary
      • 8.2.1.5. Recent Developments
    • 8.2.2. Pfizer, Inc.
    • 8.2.3. Sanofi S.A.
    • 8.2.4. Johnson & Johnson Pvt. Ltd.
    • 8.2.5. Glenmark Pharmaceuticals Ltd
    • 8.2.6. Camber Pharmaceuticals, Inc.
    • 8.2.7. Takeda Pharmaceutical Company Limited.
    • 8.2.8. Ironwood Pharmaceuticals, Inc.
    • 8.2.9. Phathom Pharmaceuticals, Inc.
    • 8.2.10. Adcock Ingram

Chapter 9. Research Process

  • 9.1. Research Process
    • 9.1.1. Data Mining
    • 9.1.2. Analysis
    • 9.1.3. Market Estimation
    • 9.1.4. Validation
    • 9.1.5. Publishing
  • 9.2. Research Attributes
  • 9.3. Research Assumption